دورية أكاديمية
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma
| العنوان: | Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma |
|---|---|
| المؤلفون: | Giachelia, M, Tisi, Mc, Martini, M, Bozzoli, V, Massini, G, D'Aló, F, Larocca, LM, Leone, G, Hohaus, S., VOSO, MARIA TERESA |
| المساهمون: | Giachelia, M, Voso, Mt, Tisi, M, Martini, M, Bozzoli, V, Massini, G, D'Aló, F, Larocca, L, Leone, G, Hohaus, S |
| سنة النشر: | 2012 |
| المجموعة: | Universitá degli Studi di Roma "Tor Vergata": ART - Archivio Istituzionale della Ricerca |
| مصطلحات موضوعية: | Adolescent, Adult, Aged, 80 and over, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocol, Carboplatin, Cyclophosphamide, Cytarabine, Doxorubicin, Female, Gene Expression Regulation, Neoplastic, Genotype, Human, Interleukin-10, Interleukin-6, Kaplan-Meier Estimate, Lymphoma, Large B-Cell, Diffuse, Male, Methylprednisolone, Middle Aged, Mitoxantrone, NF-kappa B p50 Subunit, Neoplasm Protein, Phenotype |
| الوصف: | Peripheral blood cytokines are known prognostic parameters in diffuse large B-cell lymphoma (DLBCL) treated with chemotherapy, but their role after the introduction of rituximab is unknown. Seven polymorphisms in the promoter regions of IL-6, IL-10 and NF-κB1 genes were assessed in 167 patients with DLBCL and 99 controls and correlated with interleukin-6 (IL-6) and IL-10 plasma levels. Outcome was analyzed in 137 patients treated with rituximab-based chemotherapy. The NF-κB1 - 94ATTG deletion was associated with increased IL-6 and IL-10 in DLBCL. High IL-6 concentration correlated with unfavorable prognostic factors included in the international prognostic index (IPI) and predicted for inferior progression-free (p = 0.007) and overall survival (p = 0.02). IL-6 levels remained a significant outcome predictor also including IPI as a covariate (p = 0.006 for progression-free survival). Our data suggest that the NF-κB1 genetic background influences IL-6 production in DLBCL, and that high IL-6 concentration is an independent prognostic factor also in the "rituximab era." |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/21902578; info:eu-repo/semantics/altIdentifier/wos/WOS:000300451100011; volume:53; issue:3; firstpage:411; lastpage:416; numberofpages:6; journal:LEUKEMIA & LYMPHOMA; http://hdl.handle.net/2108/115768Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84856569819 |
| DOI: | 10.3109/10428194.2011.621566 |
| الإتاحة: | https://doi.org/10.3109/10428194.2011.621566Test http://hdl.handle.net/2108/115768Test |
| رقم الانضمام: | edsbas.651372A2 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3109/10428194.2011.621566 |
|---|